Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.75 |
| ▸ | PGD | P52209 | 3/20 | 0.48 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | PGK2 | P07205 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannose 6-Phosphate SCHEMBL6599 | 1.00 | MPI (0.75) | MPIPGDPGK1PGK2S1PR4 | |
| Mannose 6-Phosphate SCHEMBL5789525 | 1.00 | MPI (0.75) | MPIPGDPGK1PGK2S1PR4 | |
| Mannose 6-Phosphate SCHEMBL349171 | 1.00 | MPI (0.75) | MPIPGDPGK1PGK2S1PR4 | |
| Mannose 6-Phosphate SCHEMBL8488 | 1.00 | MPI (0.75) | MPIPGDPGK1PGK2S1PR4 | |
| Mannose 6-Phosphate SCHEMBL3397678 | 1.00 | MPI (0.75) | MPIPGDPGK1PGK2S1PR4 | |
| Mannose 6-Phosphate SCHEMBL9736009 | 1.00 | MPI (0.75) | MPIPGDPGK1PGK2S1PR4 | |
| Mannose 6-Phosphate SCHEMBL987654 | 1.00 | MPI (0.75) | MPIPGDPGK1PGK2S1PR4 | |
| Mannose 6-Phosphate SCHEMBL5788774 | 1.00 | MPI (0.75) | MPIPGDPGK1PGK2S1PR4 | |
| Mannose 6-Phosphate SCHEMBL20798006 | 1.00 | MPI (0.75) | MPIPGDPGK1PGK2S1PR4 | |
| Mannose 6-Phosphate SCHEMBL9739836 | 1.00 | MPI (0.75) | MPIPGDPGK1PGK2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3679065-A1 | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) | California Institute of Technology (US) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019051001-A1 | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-2760477-A1 | DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS | Alnylam Pharmaceuticals, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049328-A9 | DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-12-27 | — | — | WO | disclosed |
| EP-2663548-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2013049328-A1 | DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| EP-2512449-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | The University of British Columbia (CA) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012099755-A1 | PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012016184-A2 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012016188-A2 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011143230-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011100131-A9 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011100131-A2 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011094580-A2 | CHELATED COPPER FOR USE IN THE PREPARATION OF CONJUGATED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011075656-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | WO | disclosed |
| WO-2009142822-A9 | 2-F MODIFIED RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009142822-A2 | 2-F MODIFIED RNA INTERFERENCE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-1615611-A2 | iRNA CONJUGATES | Alnylam Pharmaceuticals Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |